Effect of β-Blockers on the Left Ventricular Strain in Patients With Wild-Type Transthyretin Amyloid Cardiomyopathy Treated With Tafamidis.
Rosy Haruna Nishizawa, Hiroaki Kawano, Chisa Eguchi, Tsuyoshi Yoshimuta, Sanae Kojima, Takako Minami, Masamichi Eguchi, Shinji Okano, Satoshi Ikeda, Mitsuharu Ueda, Koji Maemura
Abstract
Open AccessBackground: Although tafamidis is used in patients with wild-type transthyretin cardiac amyloidosis (ATTRwt-CM), the effects of β-blockers, one of the conventional heart failure medications, are unclear. Therefore, this study aimed to investigate the effect of β-blockers on left ventricular function using speckle-tracking echocardiography after 1 year of treatment in patients with ATTRwt-CM. Methods and Results: We included 46 patients (median age, 78 years) with ATTRwt-CM confirmed via biopsy. We analyzed laboratory and echocardiographic data, including global longitudinal strain (GLS) to determine left ventricular strain, using 2D speckle-tracking echocardiography and compared the changes in these parameters before and 1 year after treatment with tafamidis between 24 patients who did not receive β-blockers and 22 patients who received β-blockers. The absolute GLS deterioration was higher in patients taking β-blockers by a mean of 0.48±1.55% compared with -0.68±1.65% in patients not taking β-blockers (P=0.0181). However, other conventional heart failure medications showed no change in the GLS. Conclusions: Left ventricular function may deteriorate with the use of β-blockers in patients with ATTRwt-CM treated with tafamidis for 1 year.